Demographic, Clinical, Biological, Treatment Characteristics and Cardiovascular Events of Patients With Heart Failure in Vietnam: a Multicenter Prospective Observational Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Medical Center Ho Chi Minh City (UMC)

About this trial

Describe the clinical characteristics, paraclinical features, and treatment during hospitalization, as well as at 1, 3, and 12 months post-discharge, of heart failure patients at selected cardiovascular centers in Vietnam.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged 18 years and older

Diagnosed with heart failure at the time of discharge

Have an ejection fraction (based on imaging modalities such as echocardiography or cardiac MRI) recorded closest to the time of discharge, showing a left ventricular ejection fraction of less than 50%

Disqualifiers

Patients and their relatives do not have means of communication with healthcare staff (phone, computer, messaging, etc.)

Patients do not reside in Vietnam after discharge

Trial population

All eligible patients discharged with a diagnosis of heart failure with reduced or mildly reduced ejection fraction.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Optimal treatment

    Drug

    Optimal treatment using current National Guidelines for the diagnosis and treatment of chronic heart failure

Treatment groups

2,500 Participants
are divided into 1 treatment group
Group A: Heart failure with reduced or mildly reduced ejection fraction1 intervention

Trial outcomes

Primary outcomes

1

All-cause mortality

Death from any cause

Time frame
12 months
2

Heart failure rehospitalization

Patient rehospitalization due to cardiovascular causes, excluding apparent non-cardiac causes.

Time frame
12 months

Secondary outcomes

1

Major adverse cardiovascular events

Acute myocardial infarction, stroke or death from any cause

Time frame
12 months
2

Guideline-directed medical therapy detail

Information regarding guideline-directed medical therapy, including medications used and dose titration over time.

Time frame
12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.